Male G6PD deficiency prevalence | Â | Threshold G6PD activity expressed as percent of normal | ||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
At 10% | Â | 30% | Â | Â | Â | 40% | Â | Â | Â | 60% | Â | Â | Â | 70% | Â | Â | Â | 80% | Â | Â |
 |  | M | F | T |  | M | F | T |  | M | F | T |  | M | F | T |  | M | F | T |
Domingo GJ. et al. (2019) | No. def | 500 | 124 | 624 | Â | 500 | 237 | 737 | Â | 517 | 656 | 1173 | Â | 595 | 968 | 1563 | Â | 864 | 1313 | 2177 |
 | % Def | 80 | 20 | 100 |  | 68 | 32 | 100 |  | 44 | 56 | 100 |  | 38 | 62 | 100 |  | 40 | 60 | 100 |
 | % Pop | 10.0 | 2.5 | 6.2 |  | 10.0 | 4.7 | 7.4 |  | 10.3 | 13.1 | 11.7 |  | 11.9 | 19.4 | 15.6 |  | 17.3 | 26.3 | 21.8 |
G6PD activity method | No | 502 | 513 | 1015 | Â | 502 | 513 | 1015 | Â | 502 | 513 | 1015 | Â | 502 | 513 | 1015 | Â | 502 | 513 | 1015 |
Spectrophotometric assay (n) | No. def | 50 | 12 | 62 | Â | 52 | 17 | 69 | Â | 56 | 57 | 113 | Â | 58 | 78 | 136 | Â | 79 | 99 | 178 |
 | % Def | 80.6 | 19.4 | 100.0 |  | 75.4 | 24.6 | 100.0 |  | 49.6 | 50.4 | 100.0 |  | 42.6 | 57.4 | 100.0 |  | 44.4 | 55.6 | 100.0 |
 | % Pop | 10.0 | 2.3 | 6.1 |  | 10.4 | 3.3 | 6.8 |  | 11.2 | 11.1 | 11.1 |  | 11.6 | 15.2 | 13.4 |  | 15.7 | 19.3 | 17.5 |
Automated UV enzymatic assay (n) | No. def | 52 | 14 | 66 | Â | 52 | 23 | 75 | Â | 61 | 74 | 135 | Â | 75 | 97 | 172 | Â | 99 | 125 | 224 |
 | % Def | 78.8 | 21.2 | 100.0 |  | 69.3 | 30.7 | 100.0 |  | 45.2 | 54.8 | 100.0 |  | 43.6 | 56.4 | 100.0 |  | 44.2 | 55.8 | 100.0 |
 | % Pop | 10.4 | 2.7 | 6.5 |  | 10.4 | 4.5 | 7.4 |  | 12.2 | 14.4 | 13.3 |  | 14.9 | 18.9 | 16.9 |  | 19.7 | 24.4 | 22.1 |